Cancer vaccine trial shows sharply lower recurrence in melanoma patients
Drugmakers Moderna and Merck released results on Thursday from a major study of a cancer vaccine described as the first of its kind. According to the companies, the vaccine substantially reduces the likelihood that tumors return in melanoma patients.
Why it matters
The results come from the companies that developed the vaccine, so independent review and regulatory approval remain key steps before any rollout. If confirmed, they could open the way for vaccines that help prevent cancer from returning.
Background
Therapeutic cancer vaccines aim to prompt the immune system to recognize and attack cancer cells, unlike preventive vaccines that guard against infection. The return of a tumor after initial treatment remains one of the main concerns for patients and doctors, and research of this kind seeks to address it.
This is a brief summary. The full details and context are in the original coverage.
Read the full story at سكاي نيوز عربيةThis summary was prepared with the help of AI based on the source's reporting and may contain errors. Spotted a mistake? Let us know
